Modified Vaccinia Virus Ankara-5T4 Antigen

Peritoneum Cancer

University College, LondonvaccinePhase 2Dormant

B

56/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 41/ 100
Competitive Position: 81/ 100

Competitive context

35 Active assets in the Peritoneum Cancer cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Peking University	Phase 2	BB
Docetaxel University of Pittsburgh	Phase 2	BB
Fluorouracilum City of Hope Medical Center	Phase 3	BB
Mirvetuximab Soravtansine AbbVie	Phase 3	BB
Carboplatin Qilu Hospital of Shandong University	Phase 3	BB

View all 49 →

Same molecule, other indications

Modified Vaccinia Virus Ankara-5T4 Antigen is also rated in:

renal cell carcinomaDormant

B

Indicative · Phase 2

62 / 100

clear cell renal carcinomaDormant

B

Indicative · Phase 3

60 / 100

prostate neoplasmDormant

CCC

Indicative · Phase 2

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.